BioSpace News Archive

Biotech Bay

The Top 5 Genome Sequencing Companies by Revenue

The gene sequencing industry has really taken off in recent years. Here’s a look at the top five genome sequencing companies, ranked by revenue.

April 17, 2019
·
4 min read
·
Franklin Carpenter
Drug Development

AveXis’ Phase III Data Provides More Ammo for Benefit of SMA Gene Therapy

AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.

April 17, 2019
·
3 min read
·
Mark Terry
Drug Development

First U.S. Patients Are Treated With CRISPR as Echoes of Scandal in China Still Linger

The first clinical trials using CRISPR technology are expected to get underway in the United States, even as echoes of a scandal involving the use of CRISPR on embryos in China are still being felt across the globe.

April 17, 2019
·
2 min read
·
Alex Keown
BioMidwest

BioSpace’ s Global Biopharma Roundup: April 18

Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.

April 17, 2019
·
5 min read
·
Alex Keown
Drug Development

Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA agreed - Phase III clinical trial for murepavadin in patients with nosocomial pneumonia

Murepavadin is the lead, pathogen specific, Phase III antibiotic belonging to the OMPTA family and potentially the first drug of a new class of antibiotics against Gram-negative bacteria in more than 50 years

April 17, 2019
·
4 min read
Deals

BioArctic publishes the Annual Report for 2018

BioArctic AB announced that the Annual Report for the 2018 fiscal year has been published.

April 17, 2019
·
1 min read
FDA

Karolinska Development’s portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-246

Karolinska Development’s portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes having a TP53 mutation.

April 17, 2019
·
3 min read
The National Centre for Research and Development Awards Orion Biotechnology With a Grant to Progress Development of a Treatment for Advanced Colorectal Cancer

Orion Biotechnology Canada Ltd. announced that its European subsidiary Orion Biotechnology Polska Sp. z.o.o. was awarded a grant of just under two million U.S. dollars by the Polish National Centre for Research and Development (NCBR).

April 17, 2019
·
2 min read
Business

Acting Commissioner Ned Sharpless Affirms Commitment to FDA’s Current Course

As Ned Sharpless takes over as acting commissioner of the U.S. Food and Drug Administration, he is not planning any disruptions or course corrections to the federal regulatory agency.

April 17, 2019
·
2 min read
·
Alex Keown
FDA

Circassia Pharma Receives 2nd FDA Approval for COPD Treatment in 2 Weeks

COPD is a progressive disease associated with tobacco smoking, air pollution or occupational exposure. It results in difficulties in breathing and increasing episodes of breathlessness.

April 17, 2019
·
3 min read
·
Mark Terry